questionsmedicales.fr
Maladies du système nerveux
Maladies du système nerveux central
Encéphalopathies
Épilepsie
Syndromes épileptiques
Épilepsies myocloniques
Épilepsies myocloniques : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques : Questions médicales les plus fréquentes",
"headline": "Épilepsies myocloniques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Épilepsies myocloniques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-27",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Syndromes épileptiques",
"url": "https://questionsmedicales.fr/mesh/D000073376",
"about": {
"@type": "MedicalCondition",
"name": "Syndromes épileptiques",
"code": {
"@type": "MedicalCode",
"code": "D000073376",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques progressives",
"alternateName": "Myoclonic Epilepsies, Progressive",
"url": "https://questionsmedicales.fr/mesh/D020191",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques progressives",
"code": {
"@type": "MedicalCode",
"code": "D020191",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493.063.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Épilepsie myoclonique juvénile",
"alternateName": "Myoclonic Epilepsy, Juvenile",
"url": "https://questionsmedicales.fr/mesh/D020190",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsie myoclonique juvénile",
"code": {
"@type": "MedicalCode",
"code": "D020190",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493.063.670"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques",
"alternateName": "Epilepsies, Myoclonic",
"code": {
"@type": "MedicalCode",
"code": "D004831",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Pasquale Striano",
"url": "https://questionsmedicales.fr/author/Pasquale%20Striano",
"affiliation": {
"@type": "Organization",
"name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Marte Syvertsen",
"url": "https://questionsmedicales.fr/author/Marte%20Syvertsen",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
},
{
"@type": "Person",
"name": "Deb K Pal",
"url": "https://questionsmedicales.fr/author/Deb%20K%20Pal",
"affiliation": {
"@type": "Organization",
"name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Jeanette Koht",
"url": "https://questionsmedicales.fr/author/Jeanette%20Koht",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.",
"datePublished": "2023-06-20",
"url": "https://questionsmedicales.fr/article/37339882",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1124/pharmrev.123.000906"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition.",
"datePublished": "2022-07-20",
"url": "https://questionsmedicales.fr/article/35861718",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1089/nat.2021.0101"
}
},
{
"@type": "ScholarlyArticle",
"name": "Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma.",
"datePublished": "2023-02-02",
"url": "https://questionsmedicales.fr/article/36817764",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fmed.2023.1066021"
}
},
{
"@type": "ScholarlyArticle",
"name": "The epidermal growth factor receptor in healthy pregnancy and preeclampsia.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36197759",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1530/JME-22-0105"
}
},
{
"@type": "ScholarlyArticle",
"name": "Control of cell metabolism by the epidermal growth factor receptor.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36089077",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bbamcr.2022.119359"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009422"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies du système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D002493"
},
{
"@type": "ListItem",
"position": 4,
"name": "Encéphalopathies",
"item": "https://questionsmedicales.fr/mesh/D001927"
},
{
"@type": "ListItem",
"position": 5,
"name": "Épilepsie",
"item": "https://questionsmedicales.fr/mesh/D004827"
},
{
"@type": "ListItem",
"position": 6,
"name": "Syndromes épileptiques",
"item": "https://questionsmedicales.fr/mesh/D000073376"
},
{
"@type": "ListItem",
"position": 7,
"name": "Épilepsies myocloniques",
"item": "https://questionsmedicales.fr/mesh/D004831"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Épilepsies myocloniques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Épilepsies myocloniques",
"description": "Comment diagnostiquer une épilepsie myoclonique ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'épilepsie myoclonique est-elle héréditaire ?\nQuel rôle joue l'EEG dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Épilepsies myocloniques",
"description": "Quels sont les symptômes principaux ?\nLes myoclonies sont-elles douloureuses ?\nPeut-on avoir des crises sans myoclonies ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes crises peuvent-elles survenir la nuit ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Épilepsies myocloniques",
"description": "Peut-on prévenir les crises myocloniques ?\nQuels déclencheurs sont à éviter ?\nL'éducation est-elle importante pour la prévention ?\nLe suivi médical est-il essentiel ?\nLes activités physiques sont-elles sûres ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Épilepsies myocloniques",
"description": "Quels médicaments sont utilisés pour traiter ?\nY a-t-il des traitements non médicamenteux ?\nComment évaluer l'efficacité du traitement ?\nLes traitements sont-ils à vie ?\nQuels effets secondaires des médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Épilepsies myocloniques",
"description": "Quelles complications peuvent survenir ?\nL'épilepsie myoclonique peut-elle affecter la vie quotidienne ?\nY a-t-il un risque accru de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nComment gérer les complications psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Épilepsies myocloniques",
"description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie myoclonique ?\nLes troubles neurologiques augmentent-ils le risque ?\nLe stress est-il un facteur de risque ?\nLes infections cérébrales sont-elles un risque ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une épilepsie myoclonique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical, l'examen neurologique et l'EEG."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'EEG, l'IRM cérébrale et des tests sanguins peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une épilepsie myoclonique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des secousses musculaires rapides, souvent sans perte de conscience, sont typiques."
}
},
{
"@type": "Question",
"name": "L'épilepsie myoclonique est-elle héréditaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines formes peuvent être héréditaires, nécessitant une évaluation familiale."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'EEG dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'EEG aide à détecter les anomalies électriques typiques des épilepsies myocloniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des myoclonies, des crises généralisées et parfois des absences."
}
},
{
"@type": "Question",
"name": "Les myoclonies sont-elles douloureuses ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les myoclonies ne sont généralement pas douloureuses, mais peuvent être gênantes."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des crises sans myoclonies ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent avoir des crises généralisées sans myoclonies."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la fréquence des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles survenir la nuit ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des crises myocloniques peuvent survenir pendant le sommeil."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les crises myocloniques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un traitement adéquat et l'évitement des déclencheurs."
}
},
{
"@type": "Question",
"name": "Quels déclencheurs sont à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, la fatigue, et la consommation d'alcool peuvent déclencher des crises."
}
},
{
"@type": "Question",
"name": "L'éducation est-elle importante pour la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la maladie aide les patients à mieux gérer leur condition."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il essentiel ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'ajuster le traitement et de surveiller les symptômes."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles sûres ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines activités peuvent être sûres, mais il faut éviter les sports à risque."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticonvulsivants comme le valproate et le lamotrigine sont couramment prescrits."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la thérapie comportementale et la diététique peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des crises et les effets secondaires."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, le traitement est à long terme, mais certains peuvent réduire ou arrêter."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des médicaments ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure fatigue, vertiges et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des blessures dues aux crises et des troubles psychologiques."
}
},
{
"@type": "Question",
"name": "L'épilepsie myoclonique peut-elle affecter la vie quotidienne ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut impacter la vie sociale, professionnelle et la qualité de vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de dépression ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes épileptiques ont un risque plus élevé de dépression et d'anxiété."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles entraîner des accidents ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications psychologiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un soutien psychologique et des thérapies adaptées peuvent aider à gérer ces complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, les traumatismes crâniens et certaines infections sont des facteurs."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'épilepsie myoclonique ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'épilepsie myoclonique peut débuter à tout âge, mais souvent dans l'enfance ou l'adolescence."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, d'autres troubles neurologiques peuvent augmenter le risque d'épilepsie myoclonique."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut déclencher des crises chez les personnes prédisposées."
}
},
{
"@type": "Question",
"name": "Les infections cérébrales sont-elles un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme la méningite, peuvent augmenter le risque d'épilepsie."
}
}
]
}
]
}
Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is activated by ligand binding, overexpression, or mutation. It is well known for its tyrosine kinase-dependent oncogenic activitie...
We report a novel method to inhibit epidermal growth factor receptor (EGFR) signaling using custom morpholino antisense oligonucleotides (ASOs) to drive expression of dominant negative mRNA isoforms o...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type, has often an aggressive course and is poorly responsive to current therapeutic approaches, so that 5-year survival r...
The epidermal growth factor receptor (EGFR) is expressed robustly in the placenta, and critical processes of pregnancy such as placental growth and trophoblast fusion are dependent on EGFR function. H...
The epidermal growth factor receptor (EGFR) triggers the activation of many intracellular signals that control cell proliferation, growth, survival, migration, and differentiation. Given its wide expr...
Being the most common cause of acute viral hepatitis with >20 million cases per year and 70,000 deaths annually, HEV presents a long-neglected and underinvestigated health burden. Although the entry p...
Here we identify the EGF receptor (EGFR) as a novel host factor for HEV and reveal the significance of EGFR for the HEV entry process. By utilizing RNAi, chemical modulation with Food and Drug Adminis...
Taken together, our study provides novel insights into the life cycle of HEV and identified EGFR as a possible target for future antiviral strategies against HEV....
Dysregulation of epidermal growth factor receptor (EGFR) is one of the most common mechanisms associated with the pathogenesis of various cancers. Mitogen-inducible gene 6 [MIG6; also known as ERBB re...
Odontogenic cysts and tumors develop from the dental follicle of asymptomatic impacted teeth. Odontogenic tissues express the epidermal growth factor receptor family (EGFR), which mediates cell prolif...
In this analytical study, immunohistochemical staining of EGFR and HER2 was performed on 30 normal and 30 abnormal follicles of impacted third molars. Follicles with a width of <2.5 mm were considered...
The EGFR and HER2 overall expression was high in all normal and abnormal follicles. The comparison of the percentage of stained cells and intensity of EGFR and HER2 staining in normal and abnormal fol...
Due to the high expression of EGFR and HER2 in normal and abnormal follicles, as well as the lack of significant differences in these two groups, the radiographic size of dental follicles might not in...
Activation of the epidermal growth factor receptor (EGFR) pathway is involved in the pathogenesis of asthma. Although decades of intensive research have focused on the role of EGFR in asthma, the spec...
Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in...
We analyzed paired plasma samples from patients with...
Patients whose tumors were treated with and responded to EGFRi alone were more likely to develop acquired mutations (46%) compared with those treated in combination with cytotoxic chemotherapy (9%). F...
These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominan...